Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Ilsa M. Coleman"'
Autor:
Azra Ajkunic, Erolcan Sayar, Martine P. Roudier, Radhika A. Patel, Ilsa M. Coleman, Navonil De Sarkar, Brian Hanratty, Mohamed Adil, Jimmy Zhao, Samir Zaidi, Lawrence D. True, Jamie M. Sperger, Heather H. Cheng, Evan Y. Yu, Robert B. Montgomery, Jessica E. Hawley, Gavin Ha, Thomas Persse, Patricia Galipeau, John K. Lee, Stephanie A. Harmon, Eva Corey, Joshua M. Lang, Charles L. Sawyers, Colm Morrissey, Michael T. Schweizer, Roman Gulati, Peter S. Nelson, Michael C. Haffner
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Therapeutic approaches targeting proteins on the surface of cancer cells have emerged as an important strategy for precision oncology. To capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the ex
Externí odkaz:
https://doaj.org/article/cdd085eaf0e84556a25f843f3b873e3c
Autor:
Rui M. Gil da Costa, Christine Levesque, Daniella Bianchi‐Frias, Payel Chatterjee, Hung‐Ming Lam, Carlos Santos, Ilsa M. Coleman, Pedro Ferreirinha, Manuel Vilanova, Nazaré Pinto da Cunha, Hugo Carvalho, Alexandra Moreira‐Pais, Ana Faustino‐Rocha, Tiago Neto, José Batista da Costa, Jonathan L. Wright, Rita Ferreira, Paula A. Oliveira, Joaquim Mendes, Margarida M. S. M. Bastos, Bruno Colaço, Carlos Lopes, Peter C. Black, Christopher J. Sweeney, Peter S. Nelson
Publikováno v:
Molecular Oncology, Vol 17, Iss 12, Pp 2709-2727 (2023)
Most patients with muscle‐invasive bladder cancer (MIBC) are not cured with platinum chemotherapy. Up‐regulation of nuclear factor kappa light‐chain enhancer of activated B cells (NF‐κB) is a major mechanism underlying chemoresistance, sugge
Externí odkaz:
https://doaj.org/article/c67189174a934005bc879e99ac388170
Autor:
Erolcan Sayar, Radhika A. Patel, Ilsa M. Coleman, Martine P. Roudier, Ailin Zhang, Pallabi Mustafi, Jin-Yih Low, Brian Hanratty, Lisa S. Ang, Vipul Bhatia, Mohamed Adil, Hasim Bakbak, David A. Quigley, Michael T. Schweizer, Jessica E. Hawley, Lori Kollath, Lawrence D. True, Felix Y. Feng, Neil H. Bander, Eva Corey, John K. Lee, Colm Morrissey, Roman Gulati, Peter S. Nelson, Michael C. Haffner
Publikováno v:
JCI Insight, Vol 8, Iss 7 (2023)
Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, the mecha
Externí odkaz:
https://doaj.org/article/bf1e39c95aad42bb924c7ccfb3af7d25
Autor:
Yiting Lim, Sonali Arora, Samantha L. Schuster, Lukas Corey, Matthew Fitzgibbon, Cynthia L. Wladyka, Xiaoying Wu, Ilsa M. Coleman, Jeffrey J. Delrow, Eva Corey, Lawrence D. True, Peter S. Nelson, Gavin Ha, Andrew C. Hsieh
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
Mutations in 5’ untranslated regions (UTRs) have a functional role in gene expression in cancer. Here, the authors develop a sequencing-based high throughput functional assay named PLUMAGE and show the effects of these mutations on gene expression
Externí odkaz:
https://doaj.org/article/b09e659db3294cf0bec903efcd4f8344
Autor:
Sylvan C. Baca, David Y. Takeda, Ji-Heui Seo, Justin Hwang, Sheng Yu Ku, Rand Arafeh, Taylor Arnoff, Supreet Agarwal, Connor Bell, Edward O’Connor, Xintao Qiu, Sarah Abou Alaiwi, Rosario I. Corona, Marcos A. S. Fonseca, Claudia Giambartolomei, Paloma Cejas, Klothilda Lim, Monica He, Anjali Sheahan, Amin Nassar, Jacob E. Berchuck, Lisha Brown, Holly M. Nguyen, Ilsa M. Coleman, Arja Kaipainen, Navonil De Sarkar, Peter S. Nelson, Colm Morrissey, Keegan Korthauer, Mark M. Pomerantz, Leigh Ellis, Bogdan Pasaniuc, Kate Lawrenson, Kathleen Kelly, Amina Zoubeidi, William C. Hahn, Himisha Beltran, Henry W. Long, Myles Brown, Eva Corey, Matthew L. Freedman
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
The molecular processes that lead to neuroendocrine prostate cancer after treating prostate adenocarcinoma (PRAD) are not well understood. Here the authors show that regulation by FOXA1 and changes in the epigenomic profile drive the transition from
Externí odkaz:
https://doaj.org/article/c9b61c7dcf794ef5947cc08ad8806fa3
Autor:
Daniel J. Coleman, David A. Sampson, Archana Sehrawat, Anbarasu Kumaraswamy, Duanchen Sun, Yuzhuo Wang, Jacob Schwartzman, Joshua Urrutia, Ahn R. Lee, Ilsa M. Coleman, Peter S. Nelson, Xuesen Dong, Colm Morrissey, Eva Corey, Zheng Xia, Joel A. Yates, Joshi J. Alumkal
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 6, Pp 253-262 (2020)
Neuroendocrine prostate cancer (NEPC) is the most virulent form of prostate cancer. Importantly, our recent work examining metastatic biopsy samples demonstrates NEPC is increasing in frequency. In contrast to prostate adenocarcinomas that express a
Externí odkaz:
https://doaj.org/article/d5b944dbbb4c47a8814fa347edf364fc
Autor:
W. Nathaniel Brennen, Yezi Zhu, Ilsa M. Coleman, Susan L. Dalrymple, Lizamma Antony, Radhika A. Patel, Brian Hanratty, Roshan Chikarmane, Alan K. Meeker, S. Lilly Zheng, Jody E. Hooper, Jun Luo, Angelo M. De Marzo, Eva Corey, Jianfeng Xu, Srinivasan Yegnasubramanian, Michael C. Haffner, Peter S. Nelson, William G. Nelson, William B. Isaacs, John T. Isaacs
Publikováno v:
JCI Insight, Vol 6, Iss 8 (2021)
Resistance to AR signaling inhibitors (ARSis) in a subset of metastatic castration-resistant prostate cancers (mCRPCs) occurs with the emergence of AR– neuroendocrine prostate cancer (NEPC) coupled with mutations/deletions in PTEN, TP53, and RB1 an
Externí odkaz:
https://doaj.org/article/f6df29103c0e46759e5821f89b231584
Autor:
Kenza Mamouni, Shumin Zhang, Xin Li, Yanhua Chen, Yang Yang, Jaeah Kim, Michael G. Bartlett, Ilsa M. Coleman, Peter S. Nelson, Omer Kucuk, Daqing Wu
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 8, Pp 789-799 (2018)
The high prevalence and long latency period of prostate cancer (PCa) provide a unique opportunity to control disease progression with dietary and nutraceutical approaches. We developed ProFine, a standardized composition of luteolin, quercetin, and k
Externí odkaz:
https://doaj.org/article/623cddd9c23349329ff606473a09e5ea
Autor:
Alfonso Urbanucci, Stefan J. Barfeld, Ville Kytölä, Harri M. Itkonen, Ilsa M. Coleman, Daniel Vodák, Liisa Sjöblom, Xia Sheng, Teemu Tolonen, Sarah Minner, Christoph Burdelski, Kati K. Kivinummi, Annika Kohvakka, Steven Kregel, Mandeep Takhar, Mohammed Alshalalfa, Elai Davicioni, Nicholas Erho, Paul Lloyd, R. Jeffrey Karnes, Ashley E. Ross, Edward M. Schaeffer, Donald J. Vander Griend, Stefan Knapp, Eva Corey, Felix Y. Feng, Peter S. Nelson, Fahri Saatcioglu, Karen E. Knudsen, Teuvo L.J. Tammela, Guido Sauter, Thorsten Schlomm, Matti Nykter, Tapio Visakorpi, Ian G. Mills
Publikováno v:
Cell Reports, Vol 19, Iss 10, Pp 2045-2059 (2017)
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcription factor (TF) binding. In addition, histone acetylation readers such as bromodomain-containing protein 4 (BRD4) have been shown to associate with thes
Externí odkaz:
https://doaj.org/article/a031c1acff234116bfd1c096aa18acae
Autor:
Ilsa M. Coleman, Jeffrey A. Kiefer, Lisha G. Brown, Tiffany E. Pitts, Peter S. Nelson, Kristen D. Brubaker, Robert L. Vessella, Eva Corey
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 8, Iss 10, Pp 862-878 (2006)
The clinical utility of estrogens for treating prostate cancer (CaP) was established in the 1940s by Huggins. The classic model of the anti-CaP activity of estrogens postulates an indirect mechanism involving the suppression of androgen production. H
Externí odkaz:
https://doaj.org/article/4fdc67eedb574a3f97a6270d208d79a6